Evidence Snapshot
What this grade covers
E reflects verified human therapeutic efficacy (none established); D reflects identity-verification status (exact sequence/molecular formula not independently confirmed from an authoritative analytical or regulatory source).
Regulatory Context
Not an FDA-approved drug. No verified regulatory or analytical record confirming exact chemical identity was located; sold only through research-peptide vendors.
Research Takeaway
Adamax's exact sequence/molecular formula has not been confirmed from an authoritative analytical or regulatory source; the commonly cited vendor structure (approx. Ac-MEHFPGP-[adamantylated glycine]-NH2) is presented here as unverified commercial description, not confirmed chemical identity.
See all 2 evidence claims →Quick Summary
Adamax is a name used by research-peptide vendors for a modified Semax analogue, commonly described (in commercial/vendor material only) as approximately Ac-MEHFPGP-[adamantylated glycine]-NH2. No peer-reviewed pharmacology or therapeutic-efficacy study of exact Adamax was located, and its exact sequence/molecular formula has not been confirmed from an authoritative analytical or regulatory source -- these fields are left unconfirmed here rather than filled in from vendor material. Native Semax's separately documented evidence base does not transfer to Adamax, since chemical modifications change a peptide's pharmacology; the peer-reviewed P021 literature (a different CNTF-derived, adamantane-modified peptide) is likewise not evidence for Adamax and is noted here only because both molecules are described as carrying an adamantane-related modification -- this is structural/historical context, not shared efficacy evidence. Claimed advantages over Semax -- improved blood-brain-barrier penetration, longer half-life, greater BDNF induction, or better cognition, endurance, or recovery outcomes -- have no independent verified support.
Mechanism & Research Overview
Adamax is a name used by research-peptide vendors for a modified Semax analogue, commonly described (in commercial/vendor material only) as approximately Ac-MEHFPGP-[adamantylated glycine]-NH2. No peer-reviewed pharmacology or therapeutic-efficacy study of exact Adamax was located, and its exact sequence/molecular formula has not been confirmed from an authoritative analytical or regulatory source -- these fields are left unconfirmed here rather than filled in from vendor material. Native Semax's separately documented evidence base does not transfer to Adamax, since chemical modifications change a peptide's pharmacology; the peer-reviewed P021 literature (a different CNTF-derived, adamantane-modified peptide) is likewise not evidence for Adamax and is noted here only because both molecules are described as carrying an adamantane-related modification -- this is structural/historical context, not shared efficacy evidence. Claimed advantages over Semax -- improved blood-brain-barrier penetration, longer half-life, greater BDNF induction, or better cognition, endurance, or recovery outcomes -- have no independent verified support.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Adamax's exact sequence/molecular formula has not been confirmed from an authoritative analytical or regulatory source; the commonly cited vendor structure (approx. Ac-MEHFPGP-[adamantylated glycine]-NH2) is presented here as unverified commercial description, not confirmed chemical identity.
Supported
No direct peer-reviewed therapeutic pharmacology or efficacy study of exact Adamax was located; native Semax and peer-reviewed P021 evidence do not transfer to Adamax because both involve different structural modifications from Adamax's vendor-described structure.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Research Areas Being Studied
Research areas discussed on this page reflect the Cognitive / Neuro category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
No Sources Listed Yet
Human, preclinical, regulatory, and review sources will appear here as they are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for Adamax
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.